FG-301913, an anti-CTGF mAb developed by FibroGen, Inc., is undergoing phase II clinical trials to evaluate its safety and efficacy in liver fibrosis due to chronic Hepatitis B infection and idiopathic pulmonary fibrosis. The gene discussed is CCN2; the disease is idiopathic pulmonary fibrosis.